Format

Send to

Choose Destination
Rev Alerg Mex. 2018 Oct-Dec;65(4):349-356. doi: 10.29262/ram.v65i4.382.

[Quality of life in patients with allergic asthma on treatment with omalizumab].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Instituto Mexicano del Seguro Social, Hospital General Regional 1 "Lic. Ignacio García Téllez', Servicio de Alergología, Mérida, Yucatán, México. nadiaaguilarhino@hotmail.com.

Abstract

in English, Spanish

BACKGROUND:

Omalizumab is a monoclonal antibody that controls severe allergic asthma symptoms and reduces exacerbations.

OBJECTIVE:

To analyze quality of life and respiratory function improvement using the mini-AQLQ questionnaire and spirometry, with the use omalizumab as complementary therapy to a treatment with inhaled corticosteroids and long-acting beta 2 agonists.

METHODS:

Of 30 patients with severe asthma (90 % of females, mean age, 49.1 years) the evolution of severe asthma diagnosis ranged from 1 to 24 years (average 8.3 years). All of them had at least one cutaneous or IgE-specific test that was positive to a usual aeroallergen, had total IgE determined and underwent spirometry. The mini-AQLQ questionnaire was applied and forced expiratory volume in 1 second (FEV1) was determined at baseline and at 52 weeks of omalizumab administration, the average dose of which was 550 mg, with biweekly or monthly administration.

RESULTS:

There was statistically significant improvement (p = 0.013) in the mini-AQLQ after 52 weeks, with an overall score of 4.5, mainly in the emotional (p = 0.0073) and environmental dimensions (p = 0.00014). There were no significant changes in FEV1. Obesity was observed in 63 % of patients, and overweight in 26 %.

CONCLUSIONS:

Omalizumab improved patient quality of life, with no significant changes in FEV1, probably due to obesity.

KEYWORDS:

Allergic asthma; Omalizumab; Quality of life

PMID:
30602204
DOI:
10.29262/ram.v65i4.382

Supplemental Content

Loading ...
Support Center